Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Basic toxicokinetics

Currently viewing:

Administrative data

Endpoint:
basic toxicokinetics
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: limited documentation but sufficient for evaluation

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
2008

Materials and methods

Objective of study:
toxicokinetics
Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 417 (Toxicokinetics)
Deviations:
no
GLP compliance:
not specified

Test material

Constituent 1
Details on test material:
- Name of test material (as cited in study report): 1-Butyl-3-methylimidazolium Chloride
- Physical state:
- Analytical purity: Bmim-Cl reference standard (98% Bmim-Cl)
- Radiochemical purity (if radiolabelling): [14C] Bmim-Cl was 97.5%
- Specific activity (if radiolabelling): 27.5 mCi/mmol.
- Locations of the label (if radiolabelling): RTI International (Research Triangle Park, NC)
- Stability under test conditions: stable
- Storage condition of test material: 8°C
- Lot/batch No.: 9719-75
Radiolabelling:
yes
Remarks:
C14

Test animals

Species:
rat
Strain:
Fischer 344
Sex:
male
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: rat: Harlan Sprague-Dawley, Inc. (Indianapolis, IN)
- Age at study initiation: 8–9 weeks ;
- Weight at study initiation: 161–200 g
- Fasting period before study: 12 h Animals used in the dermal or the repeated dose study were not fastened
- Acclimation period: 5-7 days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 25 °C
- Photoperiod (hrs dark / hrs light): 12 h

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Duration and frequency of treatment / exposure:
once for the absorbtion study (iv and oral)
once/ day in the 5 day accumlation study
Doses / concentrations
Remarks:
Doses / Concentrations:
50 mg/kg was administered by oral gavage (single administration)
0.5, 5 and 50 mg/kg/day by oral gavage (repeated administration)
5 mg/kg was selected for the i.v. route of administration.
No. of animals per sex per dose / concentration:
4
Control animals:
no
Details on study design:
- Dose selection rationale: oral 1/10 of the LD50; Iv 1/100 of the LD50
Details on dosing and sampling:
PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
iv application
- Tissues and body fluids sampled : urine, faeces, blood, cage washes
- Time and frequency of sampling:
Blood: 0.7.5 min h; 15 min ; 30 min; 45 min; 1 h, 1,5 h 3h; 6 h; 9h; 12 h; 24 h; 36 h; 48 h.
Other samples 6h 12 h 24 h, 48 h,

oral application (single application)
- Tissues and body fluids sampled : urine, faeces, blood, cage washes adipose tissue, blood, heart, intestine, intestinal contents, kidneys, lung, liver, muscle, spleen, stomach, stomach contents, skin, and testes.
- Time and frequency of sampling: 6h (urine only), 12 h 24 h, 48 h, 72 h


METABOLITE CHARACTERISATION STUDIES

- Tissues and body fluids sampled: urine
- Time and frequency of sampling: 6 h and 12 h
- From how many animals: Not pooled
- Method type(s) for identification: HPLC-UV/vis-radiometric analysis and LC/MS for non radioactive samples

Statistics:
mean +/- SD

Results and discussion

Toxicokinetic / pharmacokinetic studies

Details on absorption:
Systemic bioavailability was determined to be 62.1% of a 50 mg/kg oral dose in rats.
Details on distribution in tissues:
Cumulative Dose recovered from all tissues 24 h after the final dose following one or five serial daily oral administrations of Bmim-Cl (50 mg/kg/day) to male F-344 rats was 1.1 +/- 0.2 %. This is even less the cumulative dose recovery from all tissues 24 h after one administration (5.3 +/- 2.4 %). This suggest that bioaccumulation potential of BMIM Cl is low. distribution to dissues to single organs was not reported.
Details on excretion:
Urinary excretion of the parent compound by rats was the major route of elimination (i.v.: 91% in 24 h; oral: 55–74% in 24 h). The rates and routes of elimination were not affected by escalation of dose (0.5–50 mg/kg) or repeated oral administration (five daily administrations, 50 mg/kg) and were similar in male rats and B6C3F1 female mice (86–95% of dose eliminated in 24 h).

Metabolite characterisation studies

Metabolites identified:
no
Details on metabolites:
94.7 +/- 10 % of the iv applied radiactivity were recoverd as Butyl-3-methylimidazolium Chloride, no other peak was detected HPLC-UV Vis- radiometric analysis in blood and urine samples.

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): no bioaccumulation potential based on study results